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 ABSTRACT 
 Objectives  Rituximab is an effective treatment in 
patients with established rheumatoid arthritis (RA). The 
objective of the IMAGE study was to determine the 
effi cacy of rituximab in the prevention of joint damage 
and its safety in combination with methotrexate (MTX) in 
patients initiating treatment with MTX. 
 Methods  In this double-blind randomised controlled 
phase III study, 755 MTX-naïve patients with active 
RA were randomly assigned to MTX alone, rituximab 
2×500 mg + MTX or rituximab 2×1000 mg + MTX. 
The primary end point at week 52 was the change in joint 
damage measured using a Genant-modifi ed Sharp score. 
 Results  249, 249 and 250 patients were randomly 
assigned to MTX alone, rituximab 2×500 mg + MTX 
or rituximab 2×1000 mg + MTX, respectively. At 
week 52, treatment with rituximab 2×1000 mg + 
MTX compared with MTX alone was associated with a 
reduction in progression of joint damage (mean change 
in total modifi ed Sharp score 0.359 vs 1.079; p=0.0004) 
and an improvement in clinical outcomes (ACR50 65% vs 
42%; p<0.0001); rituximab 2×500 mg + MTX improved 
clinical outcomes (ACR50 59% vs 42%; p<0.0001) 
compared with MTX alone but did not signifi cantly reduce 
the progression of joint damage. Safety outcomes were 
similar between treatment groups. 
 Conclusions  Treatment with rituximab 2×1000 mg 
in combination with MTX is an effective therapy for the 
treatment of patients with MTX-naïve RA. 
 CLinicalTrials.gov identifi er NCT00299104. 
 INTRODUCTION 
 Rheumatoid arthritis (RA) is a chronic inﬂ amma-
tory disease in which early aggressive treatment 
with disease-modifying antirheumatic drugs 
(DMARDs) can improve outcomes and prevent 
joint damage. Treatment recommendations for 
the management of early arthritis concluded that 
the main goal of treatment is clinical remission, 
in order to prevent structural joint damage and 
long-term disability.  1    2  These recommendations 
acknowledge that patients with disease features of 
poor prognosis—for example, high disease activity 
and the presence of autoantibodies (rheumatoid 
factor (RF) and/or anticitrullinated peptide antibod-
ies (ACPA))—should be considered as candidates 
for the early introduction of biological therapies. 
 Incorporating biological therapies into early 
treatment regimens has shown that remission of 
disease with inhibition of progressive joint destruc-
tion is an achievable treatment goal, although this 
has primarily been limited to biological agents that 
share a common mechanism of action—namely, 
inhibition of tumour necrosis factor (TNF).  3  –  6  
 Rituximab is a therapeutic monoclonal antibody 
that selectively depletes CD20+B cells. The combi-
nation of rituximab with methotrexate (MTX) sig-
niﬁ cantly improves disease symptoms in patients 
with RA who have an inadequate response to con-
ventional DMARD therapy, and ameliorates dis-
ease symptoms and protects against joint damage 
in patients who have had an inadequate response 
to TNF inhibitors.  7  –  9  The aim of this study was to 
investigate the early therapeutic introduction of 
rituximab in patients with active RA not previously 
treated with MTX. 
 METHODS 
 Patients 
 Patients were recruited between January 2006 and 
September 2007 from 169 centres in Europe, the 
USA, Latin America, Asia and Australia. Eligible 
patients were aged 18–80 years with RA diagnosed 
according to the revised 1987 American College of 
Rheumatology (ACR) criteria.  10  Disease duration 
was ≥8 weeks but ≤4 years. Patients were not to 
have received previous treatment with MTX and 
were to have active disease deﬁ ned as a swol-
len joint count (66 joints) and tender joint count 
(68 joints) both ≥8 at screening and baseline, and 
C-reactive protein (CRP) ≥1.0 mg/dl. Patients sero-
negative for RF required radiographic evidence of 
erosive damage attributable to RA. 
 This study was conducted in accordance with the 
ethical principles of the Declaration of Helsinki and 
adhered to the principles outlined in the Guideline 
for Good Clinical Practice ICH Tripartite Guideline 
(January 1997). 
 Procedures 
 Patients were randomised to receive rituximab 
(2×500 mg or 2×1000 mg) or placebo in addition 
to initiating MTX. The randomisation schedule, 
stratiﬁ ed by region (USA or rest of world) and 
RF status (positive or negative), was generated 
by the sponsor and supplied to an Interactive 
Voice Response System (IVRS). At randomisation, 
patients were assigned unique medication and ran-
domisation numbers via the IVRS. The sponsor, 
investigators and patients were blinded to treat-
ment allocation until week 52, at which time the 
sponsor was unblinded for the purposes of data 
analysis. Rituximab/placebo was administered by 
intravenous infusion on days 1 and 15, with all 
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non-parametric tests and the closure principle for multiplicity 
adjustment, a planned sample size of 250 patients per group was 
expected to give >90% power to detect differences between 
each rituximab group and MTX alone. 
 Radiographic analyses were performed on a modiﬁ ed 
intent-to-treat (mITT) population, deﬁ ned as randomised 
patients who received study medication and for whom a 
baseline and at least one post-baseline x-ray were available. 
Missing values at week 52 were imputed by linear extrapo-
lation. For changes in radiographic scores, a global test was 
performed using the Kruskal–Wallis test to control for multi-
plicity, with primary comparisons made using a non-paramet-
ric test (Van Elteren) for the individual rituximab dose groups 
versus MTX alone, adjusting for baseline stratiﬁ cation factors 
(region and RF status). The difference in the proportions of 
patients without radiographic progression was tested using 
the Cochran–Mantel–Haenszel (CMH) test, also adjusting 
for baseline stratiﬁ cation factors; if progression status could 
not be determined, the patient was classed as ‘progressed’. 
Radiographic non-progression was deﬁ ned as a change in total 
modiﬁ ed Sharp score ≤0. 
 Clinical efﬁ cacy of rituximab versus placebo was analysed 
using the CMH test for categorical end points and analysis of 
variance (ANOVA) for continuous end points, adjusting for 
baseline stratiﬁ cation factors. ANOVA models also included the 
end point baseline value if applicable (eg, for analysis of change 
in DAS28-ESR and HAQ-DI). Missing data were imputed using 
the non-responder method for ACR, EULAR and MCR (all 
patients who withdrew or received a non-permitted DMARD 
were classed as non-responders) and the last observation carried 
forward for all other end points. 
 RESULTS 
 Overall, 755 patients were randomised with 748 included in the 
ITT and safety analyses and 715 in the mITT analysis for radio-
graphic outcomes. Baseline demographic and disease charac-
teristics were balanced across treatment groups and indicated 
that this was an early MTX-naïve RA population with highly 
active disease (mean DAS28-ESR 7.0–7.1, mean tender joint 
count 32.7–34.0, mean swollen joint count 20.0–22.4) and a 
high degree of functional impairment ( table 1 ). Approximately 
infusions ( including placebo) premedicated with intravenous 
 methylprednisolone 100 mg. Oral MTX in all patients was com-
menced at 7.5 mg/week and escalated up to 20 mg/week by 
week 8 as tolerated. 
 Repeat courses of rituximab/placebo were permitted from 
week 24. Patients eligible for re-treatment were those with a 
Disease Activity Score in 28 joints (DAS28-ESR) ≥2.6.  11  Patients 
with DAS28-ESR <2.6 were re-treated if and when this increased 
to ≥2.6. Further courses were permitted 24 weeks following each 
course based on the same criteria. 
 Concomitant glucocorticoids (≤10 mg/day prednisolone or 
equivalent) and non-steroidal anti-inﬂ ammatory drugs were 
permitted with doses kept stable. Intravenous or intramuscular 
glucocorticoids and additional DMARDs (non-biological or bio-
logical) were prohibited. 
 Radiographs of the hands, wrists and feet were performed at 
screening (considered baseline), week 24 and week 52, and read 
at a central reading facility (Synarc Inc, San Francisco, California, 
USA) by two independent expert radiologists, blinded to treat-
ment and sequence, using the Genant-modiﬁ ed Sharp scoring 
system (range 0–290).  12    13  
 The primary end point of the study was the change in total 
Genant-modiﬁ ed Sharp score (mTSS) from baseline to week 52. 
Clinical outcomes at week 52 included the proportion of patients 
achieving ACR responses relating to 20%, 50%, 70% and 90% 
improvement from baseline,  14  responses deﬁ ned according to the 
criteria of the European League Against Rheumatism (EULAR)  15  
and change in DAS28-ESR.  11  Durability of response was deter-
mined by the proportion of patients achieving a major clinical 
response (MCR; deﬁ ned as maintenance of ACR70 response 
≥6 months). Physical function was determined using the Health 
Assessment Questionnaire-Disability Index (HAQ-DI), includ-
ing the proportion of patients achieving minimum clinically 
important differences (MCID; an improvement of ≥0.22).  16  
 Adverse events were recorded throughout the study and 
graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events, version 3. 
 Statistical analysis 
 Based on simulations using distributions that match the data 
published from the ASPIRE study,  3  with data analysed using 
 Table 1  Baseline demographic and disease characteristics (intent-to-treat population) 
 
 Placebo + MTX 
(n=249) 
 Rituximab (2×500 mg) 
+ MTX (n=249) 
 Rituximab (2×1000 mg) 
+ MTX (n=250) 
Female 192 (77%) 203 (82%) 212 (85%)
Age (years) 48.1 (12.7) 47.9 (13.4) 47.9 (13.3)
Disease duration (years)
 Mean (SD) 0.91 (1.1) 0.99 (1.1) 0.92 (1.3)
 Median (range) 0.4 (0.01–8.37) 0.5 (0.00–3.95) 0.4 (0.01–11.88)
Percentage with disease duration <2 years 86 80 83
No previous DMARD therapy 174 (70%) 178 (72%) 172 (69%)
Receiving concomitant corticosteroids 119 (48%) 117 (47%) 111 (44%)
Receiving concomitant NSAIDs and/or COX-2 inhibitors 173 (69%) 179 (72%) 191 (76%)
Swollen joint count (0–66 possible joints) 20.0 (12.0) 22.4 (12.8) 21.6 (11.0)
Tender joint count (0–68 possible joints) 32.7 (16.6) 34.0 (15.7) 33.2 (15.0)
C-reactive protein (mg/dl) 3.2 (2.8) 3.4 (3.1) 3.0 (2.7)
Health Assessment Questionnaire (0–3 range) 1.8 (0.6) 1.8 (0.7) 1.7 (0.7)
DAS28-ESR 7.1 (1.0) 7.1 (1.0) 7.0 (1.0)
Rheumatoid factor positive 217 (87%) 216 (87%) 213 (85%)
Baseline mean mTSS 7.4 (10.9) 7.7 (11.7) 6.9 (10.6)
 Data are mean (SD) or number (%) unless otherwise stated. 
 COX-2, cyclo-oxygenase-2; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; 
ESR, erythrocyte sedimentation rate; mTSS, Genant-modifi ed total Sharp score; MTX, methotrexate; NSAID, non-steroidal anti-
infl ammatory drug. 
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of erosive damage and higher proportions of patients with no 
progression of joint damage (deﬁ ned as change in mTSS score 
≤0) ( table 2 ) in the rituximab 2×1000 mg + MTX group versus 
MTX alone. 
 A reduction in the progression of joint damage in the rituxi-
mab 2×1000 mg + MTX arm was evident by 24 weeks, with a 
markedly slower rate of change from 24 to 52 weeks. During 
this second 6-month period, both doses of rituximab reduced 
the progression of joint damage (including erosion and joint 
space narrowing) versus MTX alone ( ﬁ gure 2A ). 
 At week 52 both doses of rituximab + MTX were associated 
with improved clinical outcomes compared with MTX alone 
across a broad range of end points including signiﬁ cantly higher 
proportions of patients achieving ACR20, 50, 70 and 90 responses 
( table 2 ). MCRs were achieved in 8%, 18% (p=0.0015) and 21% 
(p<0.0001) of patients in the MTX alone, rituximab 2×500 mg 
and rituximab 2×1000 mg groups, respectively. 
 Greater decreases from baseline in DAS28-ESR were 
observed in both the rituximab 2×500 mg and 2×1000 mg 
groups  compared with MTX alone from week 8 through to 
week 52 ( ﬁ gure 2B ), with signiﬁ cant differences from baseline 
observed at week 52 versus MTX alone (adjusted mean −3.05 
and −3.21 vs −2.06; p<0.0001 for both). Within both rituxi-
mab groups the incidence of remission (deﬁ ned as DAS28-ESR 
<2.6) increased throughout the study period and by week 52 
was achieved in 13%, 25% and 31% in the MTX alone, rituxi-
mab 2×500 mg and rituximab 2×1000 mg groups, respectively 
(p<0.001 for both rituximab groups; see table 2 and ﬁ gure S2 in 
online supplement). EULAR good responses were achieved in 
signiﬁ cantly higher proportions of patients in both rituximab 
groups versus MTX ( table 2 ). 
 Improvement in function as determined by mean changes in 
the HAQ-DI from baseline to week 52 was signiﬁ cantly greater 
in the rituximab 2×500 mg and 2×1000 mg groups compared 
with MTX alone (−0.905 and −0.916 vs −0.628, respectively; 
p<0.0001 for both), with higher proportions of patients achiev-
ing an MCID than in the MTX alone group ( table 2 ). 
 Effi cacy in subgroups 
 Subgroup analysis indicated that treatment effects were observed 
across multiple end points in the majority of subgroups based 
on baseline characteristics (change in mTSS across subgroups 
is shown in table S1 in the online supplement). This included 
patients with high disease activity, elevated inﬂ ammatory mark-
ers, and RF- and/or ACPA-seropositive disease. Responses in 
patients seropositive for RF and/or ACPA were enhanced com-
pared with patients seronegative for both autoantibodies across 
most end points ( table 2 ). As with all subgroups with relatively 
small sample sizes, the data in the seronegative subgroup should 
be interpreted with caution. 
 Safety outcomes 
 Adverse events were reported in 81%, 76% and 79% of patients 
treated with MTX alone, rituximab 2×500 mg or rituximab 
2×1000 mg, respectively, with serious adverse events in 10%, 
9% and 10%, respectively ( table 3 ). Adverse events leading to 
withdrawal included exacerbation of RA (ﬁ ve patients in the 
MTX alone group) and infusion-related reactions (one patient in 
the rituximab 2×500 mg group and three patients in the rituxi-
mab 2×1000 mg group). There were three deaths (two cases of 
pneumonia, including a case of  Pneumocystis jiroveci pneumonia 
(PJP) and one cerebral infarct), all of which occurred in the MTX 
alone group. 
90% of treated patients completed up to the week 52 primary 
end point, with the primary reason for early withdrawal in all 
groups being lack of therapeutic response ( ﬁ gure 1 ). 
 Most patients (80–84%, balanced across treatment groups) 
received a second course of treatment. The majority of sec-
ond courses (approximately 80%) were administered by week 
30. A higher proportion of patients treated with MTX alone 
received a third course compared with either rituximab group 
(44% vs 37% and 36%, respectively). The mean dose of MTX 
was >18 mg/week in all groups by week 8 (median dose 
19–20 mg/week). 
 At the week 52 primary end point analysis, rituximab 
2×1000 mg + MTX was associated with a signiﬁ cant reduction 
in the progression of joint damage compared with MTX alone 
(mean change in mTSS 0.359 vs 1.079; p=0.0004;  table 2 ). The 
robustness of the primary outcome was supported by numer-
ous sensitivity analyses, including the per-protocol analysis 
and analyses using various imputation rules for missing data. 
A cumulative probability plot showing the change from base-
line to week 52 in mTSS for the ITT population (ﬁ gure S1 
in online supplement) shows that the highest proportion of 
non- progressors was observed in patients in the rituximab 
2×1000 mg group. Patients with larger changes in mTSS, and 
therefore more rapid progression, were mainly limited to the 
MTX alone group (see ﬁ gure S1 in online supplement). 
 Although slower progression of joint damage was also 
observed with rituximab 2×500 mg + MTX, the difference did 
not achieve statistical signiﬁ cance compared with MTX alone. 
An exploratory analysis indicated that rituximab 2×1000 mg 
+ MTX resulted in slower progression of joint damage versus 
rituximab at the lower dose (p=0.0369). This apparent differ-
ence between the rituximab doses was extensively explored 
and did not appear to be due to small numbers of rapidly pro-
gressing patients in the lower dose group; indeed, separation 
of the doses was observable from the 70th percentile. Multiple 
robustness analysis also demonstrated signiﬁ cant outcomes 
only with the higher dose. 
 Secondary radiographic end points reﬂ ected that of the 
 primary assessment, with signiﬁ cantly reduced progression 
 Figure 1  Patient disposition. *Patients are grouped according to 
treatment received. Note that seven patients were randomised and not 
treated; these patients are grouped under their randomised treatment 
group (two placebo + MTX, three rituximab 2×500 mg + MTX, two 
rituximab 2×1000 mg + MTX); three patients received incorrect 
medication for their fi rst treatment course (one placebo + MTX patient 
received rituximab 2×500 mg; one rituximab 2×500 mg + MTX 
patient received placebo + MTX; one rituximab 2×1000 mg + MTX 
patient received placebo + MTX). MTX, methotrexate. 
755 Random assigned
252* Placebo + MTX 252* Rituximab
(2 x 500 mg)
+ MTX
251* Rituximab 
(2 x 1000 mg)
+ MTX
39 Total withdrawals (15.5%)
5 Adverse events (2.0%)
19 Lack of efficacy (7.5%)
2 Protocol violations (0.8%)
8 Patient request (3.2%)
5 Other (2.0%)
25 Total withdrawals (9.9%)
3 Adverse events (1.2%)
9 Lack of efficacy (3.6%)
2 Protocol violations (0.8%)
9 Patient request (3.6%)
2 Other (0.8%)
21 Total withdrawals (8.4%)
3 Adverse events (1.2%)
4 Lack of efficacy (1.6%)
0 Protocol violations (0%)
5 Patient request (2.0%)
9 Other (3.6%)
213 Completed 52 weeks 
(84.5%)
227 Completed 52 weeks
 (90.1%)
230 Completed 52 weeks
(91.6%)
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 DISCUSSION 
 This is the ﬁ rst study of initiating a targeted B cell therapy in 
MTX-naïve patients with active RA. Over 52 weeks the study 
showed that, compared with MTX alone, rituximab 2×1000 mg + 
MTX was signiﬁ cantly more effective in inhibiting the progres-
sion of joint damage and in improving clinical outcomes in a 
population of patients with RA, of whom approximately 90% 
were seropositive for RF and/or ACPA autoantibodies. Although 
the lower dose of rituximab (2×500 mg) was associated with 
improved symptoms, this dose did not meet the primary end 
point of reducing joint damage. 
 Both doses of rituximab were highly effective in relieving 
the signs and symptoms of RA. Importantly, the proportions 
of patients achieving high-hurdle end points, including those 
with 90% improvement in their disease symptoms (ACR90) 
 Infusion-related reactions, consisting predominantly of 
throat irritation, pruritus, rash and fever, were most frequent in 
patients in the rituximab 2×1000 mg + MTX group; however, 
this was apparent only for the ﬁ rst infusion of the ﬁ rst course 
with frequency of infusion-related reactions similar in all groups 
thereafter ( table 3 ). 
 Serious infections were reported more frequently in the MTX 
alone group (5%) than in either rituximab group (2% and 3% for 
the 2×500 mg and 2×1000 mg groups, respectively), with rates 
of serious infections per 100 patient-years’ exposure also higher 
in this group ( table 3 ). There were two opportunistic infections 
(both PJP), one in the rituximab 2×500 mg group, which resolved 
with treatment, and one in the MTX alone group, which was 
fatal. Progressive multifocal leucoencephalopathy was not 
observed in this study. 
 Figure 2  (A) Progression of joint damage from baseline to 24 weeks and from 24 to 52 weeks (intent-to-treat population). *Adjusted p values versus 
placebo. Missing values were imputed using linear extrapolation using baseline and week 24 radiographs. (B) Change in DAS28-ESR over 52 weeks 
(intent-to-treat population). Error bars represent ±1.96×SEM. DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; MTX, 
methotrexate. 
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is unusual. A deﬁ nitive explanation is unknown; however, 
one hypothesis may be related to the ability of the rituximab 
2×1000 mg dose to induce more complete B cell depletion in 
non-peripheral compartments.  20    21  In this model, more pro-
nounced depletion of synovial B-lineage cells is required for 
radiographic relative to clinical outcomes. Thus, the inﬂ uence 
of B cells may have a different dynamic to the effects that are 
related to clinical responses. This hypothesis may be supported 
by studies in monkeys, which have shown greater B cell deple-
tion in lymphoid tissues following repeat treatments.  22  Given 
that a high proportion of patients in all groups received re- 
treatment in the current study, more complete depletion in the 
synovium following re-treatment may provide some explana-
tion as to the enhanced effect on joint damage observed in the 
second half of the study. 
 This observation also suggests that the labelled dose of rituxi-
mab 2×1000 mg remains appropriate since this was the only 
dose that both improved clinical symptoms and signiﬁ cantly 
inhibited progression of joint damage. However, whether con-
tinued repeat treatment with this dose or the lower dose of 
2×500 mg is optimal has not been addressed in this study and is 
perhaps an area for further investigation. 
 Importantly, compared with MTX alone, improved clinical 
and radiographic outcomes were observed with rituximab + 
MTX in patients with accepted markers of progressive disease 
(eg, high disease activity or CRP). Consistent with previous 
as well as those achieving DAS28-ESR remission, were sig-
niﬁ cantly greater with rituximab + MTX compared with MTX 
alone. Responses were sustained over time, as demonstrated by 
signiﬁ cantly higher proportions of patients achieving an MCR 
in both rituximab groups. Functional ability was also improved 
with signiﬁ cantly greater mean changes in the HAQ-DI in both 
rituximab treatment groups compared with MTX alone, as well 
as higher proportions of patients achieving clinically meaningful 
changes. Given that the HAQ-DI is a major predictor of work 
disability as well as costs of disease treatment,  17  its signiﬁ cant 
improvement in this young and functionally impaired patient 
population is of particular clinical relevance. 
 Rituximab 2×1000 mg signiﬁ cantly reduced the progression 
of joint damage within 6 months. Importantly, the degree of 
inhibition was notably greater from weeks 24 to 52, with a 91% 
reduction in the progression of joint damage compared with 
MTX alone. Exploratory analysis also showed signiﬁ cant effects 
on reducing joint damage in the rituximab 2×500 mg group 
during this second 6-month period. The slower onset of radio-
graphic inhibition with this dose is in contrast to that observed 
for clinical outcomes, which were comparable over time for 
both doses of rituximab ( ﬁ gure 2B ). Disconnects between clini-
cal responses and radiographic outcomes with rituximab and 
with TNF inhibitors have been reported  18    19  ; however, the 
ﬁ nding that different doses of the same therapeutic agent have 
similar clinical effects but differential radiographic outcomes 
 Table 3  Summary of safety profi le over 52 weeks (safety population) 
  Placebo + MTX (n=250) 
 Rituximab (2×500 mg) 
+ MTX (n=249) 
 Rituximab (2×1000 mg) 
+ MTX (n=249) 
Treated fi rst course 250 249 249
Patient-years of observation 229.75 238.77 241.06
AE incidence: no. of patients (%)
 Any AE 203 (81%) 189 (76%) 197 (79%)
 Any serious AE  26 (10%)  23 (9%)  24 (10%)
 Serious AE in >1 patients
  Pneumonia   3 (1%)   1 (<1%)   2 (<1%)
  Urinary tract infection   2 (<1%)   1 (<1%) –
  Appendicitis –   2 (<1%) –
  RA fl are   1 (<1%) –   2 (<1%)
AE leading to withdrawal  12 (5%)   4 (2%)   5 (2%)
Death   3 (1%)   0   0
Infusion-related reaction
 First course*  31 (12%)  35 (14%)  46 (18%)
 Second course*  20 (10%)  19 (9%)  22† (10%)
 Third course*   7 (6%)   2 (2%)   9 (10%)
 Serious infusion-related reactions – –   1 (<1%)‡
Infection
 Any 124 (50%) 127 (51%) 129 (52%)
 Serious§  13 (5%)   6 (2%)  8 (3%)
Cardiac event
 Any   3 (1%)   3 (1%)  8 (3%)
 Serious –   2 (<1%)  3 (1%)
Vascular event
 Any  17 (7%)  19 (8%)  21 (8%)
 Serious   2 (<1%)   2 (<1%)   1 (<1%)
Malignancy
 Any   5 (2%)   2 (<1%)   1 (<1%)
 Serious   4 (2%)   2 (<1%)   1 (<1%)
AE rates per 100 patient-years (95% CI)
 Overall infection rate 115 (101.85 to 129.6) 103.87 (91.71 to 117.6) 126.52 (113.09 to 141.5)
 Serious infection§ rate   6.09 (3.61 to 10.29)   4.61 (2.55 to 8.32)   3.73 (1.94 to 7.18)
 *Percentage incidence based on number receiving each treatment course. 
 †One of these infusion-related reactions was reported as serious. 
 ‡Anaphylactic reaction during the second infusion of the second course. 
 §Reported as serious and/or treated with intravenous antibiotics. 
 AE, adverse event; MTX, methotrexate; RA, rheumatoid arthritis. 
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reports,  23    24  outcomes were enhanced in patients seropositive 
for RF or ACPA at baseline compared with patients who were 
seronegative for both. 
 The safety proﬁ le in this early RA cohort is consistent with 
that published with rituximab in patients with later stage dis-
ease  7    25  with no new or unexpected safety ﬁ ndings observed. 
The rate of serious infection was low and consistent with rates 
previously published for rituximab in RA.  26  Two opportunis-
tic infections were reported, both of which were cases of PJP 
(including one in a patient receiving MTX alone with a fatal 
outcome). Although the incidence of PJP in patients with RA 
is thought to be low, cases have been reported with low-dose 
MTX as well as in patients treated with biological therapies.  27    28  
With the exception of the frequency of infusion-related reac-
tions to the ﬁ rst infusion of the ﬁ rst treatment course, the 
safety proﬁ les between the two rituximab dose groups were 
comparable. 
 In summary, this is the ﬁ rst evidence that targeted B cell 
depletion with rituximab 2×1000 mg + MTX is an effective and 
well-tolerated therapy for the treatment of MTX-naïve RA. The 
critical treatment goals of disease remission, inhibition of joint 
damage and improved functional ability were all signiﬁ cantly 
improved compared with the standard of care treatment (MTX) 
in this important patient population. 
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